Accordingly, most individuals with consistently elevated intraocular pressures of greater than 21mmHg, particularly if they have other risk factors, are treated in an effort to prevent vision loss from glaucoma.
[11][12] Increased IOP without glaucomatous changes (in optic disc or visual field) is considered as ocular hypertension.
Treatment, by lowering the intraocular pressure, may help decrease the risk of vision loss and damage to the eye from glaucoma.
Eye drop formulations often include different combinations of beta-blockers, prostaglandin analogs (for example, latanoprost, travoprost, and bimatoprost), diuretics, and alpha-agonists.
[citation needed] Laser treatment may be more effective than medications for decreasing the speed of loss of the visual field in people who have open-angle glaucoma.
[23] That same year, European Glaucoma Preventing Study (EGPS) published a study from European data demonstrating no significant difference between using a drug called dorzolamide and placebo for lowering intraocular pressure and therefore no significant difference in development of glaucoma.
[25] More recently in 2019, The LiGHT trial compared the effectiveness of eye drops and selective laser trabeculoplasty for ocular hypertension and open angle glaucoma.